Fill Finish Manufacturing Market Size & Share 2025 - 2034

Fill Finish Manufacturing Market Size

The global fill finish manufacturing market was valued at USD 13.6 billion in 2024 and is projected to grow from USD 14.7 billion in 2025 to USD 32.8 billion by 2034, expanding at a CAGR of 9.3%. The growth of the market is driven by several factors, including advancements in manufacturing technologies, the expansion of the biopharmaceutical industry, and the increasing adoption of prefilled syringes for parenteral drug delivery.

Fill finish manufacturing represents a critical stage in the pharmaceutical and biopharmaceutical production process, involving the sterile filling of drug products such as vaccines and biologics into containers like vials, ampoules, prefilled syringes, and cartridges, followed by sealing and capping. Key players in this market include Becton, Dickinson and Company, Gerresheimer, I.M.A. Industria Macchine Automatiche, SCHOTT Pharma, and Bausch+Ströbel.
 

The market value increased from USD 10.2 billion in 2021 to USD 12.6 billion in 2023, largely due to the COVID-19 pandemic, which significantly boosted vaccine demand. This surge created a heightened need for sterile vials and advanced instruments for filling and sealing vaccine vials during COVID-19 vaccine production. For example, SCHOTT Pharma supplied approximately 380 million vials in India for vaccine manufacturing during the pandemic.
 

The growing adoption of prefilled syringes for parenteral drug delivery is a key factor driving market growth. Prefilled syringes enhance drug delivery efficiency by reducing dosing errors and contamination risks. This trend is particularly important for injectable drugs such as vaccines and biologics, where sterility and precision are critical. The increasing development and regulatory approval of injectable biologics and vaccines further fuel demand for advanced prefilled syringes, including Ready-To-Use (RTU) options. For instance, data from the Center for Biologics Evaluation and Research (CBER) indicates that 22 new biologics license applications were submitted in 2023, nearly double the number recorded in 2021 and 2022. Additionally, the European Journal of Medicinal Chemistry reported that the FDA approved 17 biologics license applications in 2023. This rise in biologics approvals is expected to drive the demand for prefilled syringes. Furthermore, pharmaceutical companies are increasingly investing in automated filling lines, sterile packaging solutions, and quality control systems, further supporting market growth.
 

Technological advancements in fill finish manufacturing processes are also positively impacting the market. Innovations such as automated inspection systems, advanced robotics, and isolator-based filling lines have enhanced the accuracy and sterility of drug packaging. These technologies minimize cross-contamination risks, reduce human intervention, and enable high-throughput production, which is essential for meeting global demand.
 

Overall, fill finish manufacturing remains a critical phase in the pharmaceutical and biopharmaceutical industries, ensuring the sterile and precise packaging of drug products such as vaccines and biologics into containers like vials, ampoules, prefilled syringes, and cartridges, followed by sealing and capping.
 

Fill Finish Manufacturing Market Trends

• The global expansion of pharmaceutical and biopharmaceutical industries is a key factor driving the growth of the fill-finish manufacturing market.
   
• For example, according to the India Brand Equity Foundation, India hosts approximately 3,000 drug companies and 10,500 drug manufacturing units.
   
• As pharmaceutical companies and manufacturing facilities continue to grow, the demand for advanced and efficient fill-finish equipment for the sterile packaging of various drug formulations is also increasing.
   
• Additionally, emerging markets, particularly in regions such as Asia, Africa, and Latin America are significantly contributing to market growth through substantial investments in healthcare, industrial infrastructure, and education.
   
• For instance, the Indian government has proposed a budget allocation of USD 602.9 million for the Department of Pharmaceuticals for the fiscal year 2025-2026, marking a 28.8% increase from the USD 468 million allocated for the fiscal year 2025.
   
• Such budgetary initiatives are creating new opportunities for fill-finish product manufacturers to supply advanced equipment and consumables to newly established pharmaceutical facilities and to upgrade existing ones, thereby driving market growth.
   

Fill Finish Manufacturing Market Analysis

The global market was valued at USD 10.2 billion in 2021. The market size reached USD 12.6 billion in 2023, from USD 11.9 billion in 2022.
 

Based on the product, the market is segmented into consumables and instruments. The consumables segment dominated the market in 2024, holding the largest share due to the extensive use of items such as prefilled syringes (PFS), vials, and cartridges in large volumes for drug production, leading to consistent and high demand. This segment was valued at USD 10.2 billion in 2024 and is projected to reach USD 24.2 billion by 2034, growing at a CAGR of 9.2%.
 

This growth is largely attributed to the rising prevalence of chronic disease conditions and the associated demand for vaccines, biologics, and precision medicine, the market for which is estimated to reach USD 157.1 billion by 2032. In comparison, the instruments segment, valued at USD 3.5 billion in 2024, is expected to grow to USD 8.6 billion by 2034, with a CAGR of 9.6%.
 

• Consumables such as vials, prefilled syringes, and cartridges are extensively utilized in large volumes for the production of various injectable drug delivery systems. These consumables are critical for ensuring accurate dosing, maintaining sterility, and enabling safe drug administration.
   
• Their single-use nature and essential role in drug packaging contribute to their high consumption rates across pharmaceutical manufacturing processes.
   
• Additionally, the increasing demand and regulatory approvals for new vaccines and biologics globally, driven by the prevalence of chronic diseases, are further boosting the need for these consumables in the filling and packaging of drug formulations to meet growing global requirements.
   
• For example, according to Gerresheimer's 2022 investor presentation, the company produced approximately 3.5 billion injection vials in a single year. This highlights the significant scale of consumable usage and their pivotal role in supporting the production, packaging, and distribution of various drug formulations.
   
• As the demand for vaccines and biologics continues to rise, the need for high-quality consumables is expected to grow, driving the segment's expansion.
   

Based on application, the fill finish manufacturing market is segmented into parenteral drug delivery, biologics manufacturing, personalized medicines, and other applications. In 2024, the parenteral drug delivery segment held the largest market share at 44.4%. Meanwhile, the personalized medicines segment, valued at USD 2.2 billion in 2024, is projected to reach USD 5.5 billion by 2034.
 

• The parenteral drug delivery segment dominates the market due to its extensive use in treating various chronic and acute diseases. Parenteral delivery systems, including intramuscular, intravenous, and subcutaneous injections, are highly preferred for their rapid onset of action, precise dosing, and high bioavailability.
   
• The increasing prevalence of chronic diseases is driving the demand for injectable therapies. For example, data from the Centers for Disease Control and Prevention (CDC) highlights that in 2019, the United States reported 8,916 cases of tuberculosis, 58,371 cases of Salmonella, 34,945 cases of Lyme disease, and 371 cases of meningococcal disease.
   
• As the incidence of infectious diseases rises, the demand for effective parenteral antibiotics grows, boosting the production of parenteral drug delivery systems. This trend is fueling the need for advanced fill-finish instruments and consumables for the sterile packaging, labeling, and sealing of parenteral drug formulations, thereby driving the growth of this segment in the fill-finish manufacturing market.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the fill finish manufacturing market is segmented into pharmaceutical and biopharmaceutical companies, contract manufacturing organizations, and other end users. The pharmaceutical and biopharmaceutical companies segment accounted for the highest market share of 53.3% in 2024.
 

• The dominance of the pharmaceutical and biopharmaceutical companies segment is primarily driven by their critical role in the production, development, and commercialization of various drug products, particularly injectable formulations such as vaccines, biologics, and personalized therapies.
   
• Pharmaceutical and biopharmaceutical companies typically operate large-scale manufacturing processes, necessitating the use of advanced fill-finish instruments and consumables to ensure sterile, precise, and regulatory-compliant packaging of drug formulations.
   
• Additionally, the increasing approval rates of drug formulations, including personalized medicines, are driving the demand for advanced fill-finish manufacturing systems to scale production and meet growing global requirements.
   
• For example, in 2024, the U.S. Food and Drug Administration (FDA) approved 18 new personalized medicines for various disease conditions.
   
• As the approval rates for new drugs continue to rise, the demand for advanced fill-finish manufacturing systems is expected to grow. These systems are essential for maintaining the sterility and stability of drug formulations during packaging, sealing, and labeling, thereby contributing to the market's expansion.
   

North America dominated the fill finish manufacturing market, with the highest market share of 37% in 2024. The region has advanced healthcare infrastructure, and the rate of adoption of innovative fill finish manufacturing products is also high. Further, the region is home to numerous contract manufacturing organizations (CMOs) that specialize in fill finish operations, thereby propelling the growth of this market.
 

• The U.S. market was valued at USD 3.4 billion and USD 4 billion in 2021 and 2022, respectively. In 2024, the market size reached USD 4.6 billion from USD 4.2 billion in 2023.
   
• The growth of the market is driven by factors such as the expansion of biotechnological and pharmaceutical manufacturing, increased regulatory focus on quality control, and the rising number of drug approvals by the U.S. FDA.
   
• For instance, the Center for Drug Evaluation and Research (CDER) reported an average of 47 novel drug approvals annually in the U.S. between 2015 and 2024.
   
• As the rate of regulatory approvals continues to rise, the production of these novel drugs is also increasing. This trend is driving the demand for fill-finish manufacturing products to ensure sterile packaging, labeling, and sealing, thereby contributing to market growth in the country.
   

Europe fill finish manufacturing market accounted for USD 4 billion in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• The growth of the market in the region is primarily driven by the increasing aging population, as older adults are more susceptible to infectious diseases.
   
• According to the European Commission, 21.1% of the EU population was aged 65 or older in 2022, and this figure is projected to rise to 32.5% by 2100.
   
• As the aging population grows, the demand for injectable drugs used in chronic disease management is expected to increase. This trend is likely to boost the need for consumables such as vials, ampoules, and prefilled syringes for injectable packaging, thereby driving market growth across the region.
   
• Additionally, the growth of the fill finish manufacturing industry in Europe is also driven by the increasing demand for biologics and sterile injectables. Pharmaceutical companies are heavily investing in sterile drug production, fueled by the rising prevalence of chronic diseases and advancements in treatments such as GLP-1s, biosimilars, and vaccines, specifically in countries such as Germany, UK, France, Spain, and Italy.
   

Germany fill finish manufacturing market is projected to experience steady growth between 2025 and 2034.
 

• The market's growth is primarily driven by the increasing demand for aseptic processing in drug and vaccine manufacturing. Factors such as a skilled workforce, advanced healthcare infrastructure, and a strong focus on healthcare innovation position the country as a key destination for investments in fill finish capabilities.
   
• Germany offers an ideal environment for the development and production of high-quality, research-intensive pharmaceutical products. In 2022, the pharmaceutical sector in Germany invested over USD 11.3 billion in research and development, surpassing all other EU nations. The country also leads Europe in pharmaceutical innovation, with 613 patents registered with the European Patent Office in 2022. Additionally, Germany conducted 524 clinical trials funded by research-based pharmaceutical companies in 2022, ranking second in the EU and fourth globally, following the United States, China, and Spain.
   
• Additionally, collaborations between contract manufacturing organizations and pharmaceutical companies are further propelling the market's expansion.
   

The Asia Pacific region is projected to be valued at USD 3.4 billion in 2024 and is expected to reach USD 8.4 billion by 2034.
 

• The growth in the region is primarily driven by the rising prevalence of chronic diseases such as cancer and infectious diseases. For example, data from the Journal of Wiley indicates that in 2022, nearly 49.2% of all cancer cases were reported in Asia.
   
• As the incidence of these chronic conditions continues to rise, the demand for effective vaccines and biologics is increasing. This, in turn, drives the need for sterile containers like vials, ampoules, and prefilled syringes for filling and packaging purposes, thereby fuelling market growth in the region.
   

Japan fill finish manufacturing market is poised to witness lucrative growth between 2025 - 2034.
 

• This market expansion is primarily fueled by the country’s strong emphasis on high-quality production standards and strict adherence to Good Manufacturing Practices (GMP), which are predominantly supported by semi-automated and automated fill finish manufacturing technologies.
   
• Moreover, the growing demand for pharmaceuticals, especially in response to the country’s elderly population, further creates a need for specialized and customized drug manufacturing solutions, propelling the market growth in the region.
   

Brazil is experiencing significant growth in the fill finish manufacturing market.
 

• The growth of Brazil's biopharmaceutical industry, particularly in the biologics and biosimilars segments, is driving the demand for advanced fill-finish technologies.
   
• This growth is supported by an increase in regulatory approvals for biologics and rising investments from both domestic and international pharmaceutical companies to enhance production capabilities and address growing healthcare demands.
   
• By May 2023, Brazil had approved 52 follow-on biological medicines, with approximately 30 additional biological products either in the testing phase or awaiting approval from the Brazilian Health Regulatory Agency (ANVISA).
   

The fill finish manufacturing market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• Saudi Arabia's market growth is driven by initiatives under ‘Vision 2030,’ which emphasize the development of the healthcare and life sciences sectors.
   
• In addition, growing approval for biologics and biosimilars in the country is also increasing the demand for fill finish manufacturing. For instance, as per Princess Nourah bint Abdulrahman University, Saudi Food and Drug Authority (SFDA) biologics approval in Saudi Arabia increased from 5 approvals during 2005-2009 to 38 approvals during 2015-2019. Further, in 2024, 10 biological drugs were approved by the SFDA.
   
• The government's focus on upgrading infrastructure and adopting advanced technologies in the pharmaceutical and biopharmaceutical industries is boosting the demand for advanced fill finish manufacturing systems. These systems are essential for the production and packaging of various drug formulations within the country.
   

Fill Finish Manufacturing Market Share

• Key players, including Becton, Dickinson and Company, Gerresheimer, I.M.A. Industria Macchine Automatiche, SCHOTT Pharma, and Bausch+Ströbel, collectively hold 31.6% of the global market share. These companies maintain their leadership through diverse product portfolios, strategic collaborations, regulatory approvals, and ongoing innovation. Becton, Dickinson and Company stands out due to their comprehensive range of prefilled syringes, widely adopted in pharmaceutical and biopharmaceutical applications.
   
• Becton, Dickinson and Company and SCHOTT Pharma have strengthened their market positions through product launches. In September 2024, Becton, Dickinson and Company introduced the BD Neopak XtraFlow Glass Prefillable Syringe and expanded the capacity of its BD Neopak Glass Prefillable Syringe platform to address the growing demand for biologic therapies. This launch enhanced the company's competitive standing in the market.
   
• Furthermore, in January 2024, SCHOTT Pharma launched glass vials designed for deep-cold storage of drugs. These vials are specifically engineered to store vaccines, gene therapies, and mRNA-based medications requiring freezing and transportation at temperatures as low as -80°C. Traditional vials often experience glass breakage during freezing and thawing due to thermal stress, leading to costly disruptions and drug losses. This product introduction expanded SCHOTT Pharma's portfolio and contributed to revenue growth.
   

Fill Finish Manufacturing Market Companies

Few of the prominent players operating in the fill finish manufacturing industry include:
 

• AST
• Bausch+Ströbel
• Becton, Dickinson and Company
• Borosil Scientific
• Corning Incorporated
• Gerresheimer
• Groninger
• I.M.A. Industria Macchine Automatiche
• Kishore Group
• Maquinaria Industrial Dara
• Nipro
• SCHOTT Pharma
• SGD Pharma
• Steriline
• Stevanato Group

• Becton, Dickinson and Company

Becton, Dickinson and Company leverages a global workforce exceeding 70,000 employees, enabling the company to drive innovation and deliver high-quality solutions efficiently across its markets.
 

• SCHOTT Pharma

SCHOTT Pharma operates in over 34 countries, supported by a comprehensive network of distributors. This extensive distribution framework enhances the company’s global market presence and accessibility.
 

• Stevanato Group

Stevanato Group is a leading manufacturer of glass cartridges, including both bulk and pre-sterilized formats, for pen injectors. The company is also the largest producer of EZ-fill pre-sterilized vials and ranks as the second-largest manufacturer of glass syringes globally.
 

Fill Finish Manufacturing Industry News:

• In May 2025, SCHOTT Pharma expanded its cartriQ portfolio by introducing a 1.5 ml small-volume ready-to-use (RTU) sterile cartridge for human use. This addition, the smallest sterile format in the portfolio to date, is specifically designed to support the stable storage of sensitive medications such as insulin, GLP-1 drugs, and hormone therapies. This launch aligns with SCHOTT Pharma’s strategic focus on providing high-value solutions, further strengthening its leadership in the fill-finish manufacturing market.
   
• In September 2024, SCHOTT Pharma, Gerresheimer, and Stevanato Group announced a strategic collaboration under the “Alliance for RTU” initiative. This partnership aims to accelerate the adoption of ready-to-use (RTU) vials and cartridges by sharing technical expertise and promoting the benefits of RTU containers among pharmaceutical companies, CMOs, and CDMOs.
   
• In October 2024, Nipro entered a strategic collaboration with Corning to integrate Corning’s proprietary Velocity Vial coating technology into Nipro’s high-quality Type I borosilicate glass vials. This partnership focuses on enhancing pharmaceutical packaging by improving filling-line efficiency by 20–50% and reducing glass particulates, cracks, and cosmetic defects. The collaboration strengthens Nipro’s position in the injectable drug packaging market by offering innovative, low-friction vial solutions that lower total ownership costs and improve product quality, helping pharmaceutical companies optimize performance while maintaining the highest safety and quality standards.
   

The fill finish manufacturing market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Consumables
  • Prefilled syringes (PFS)
    • Glass PFS
    • Plastic PFS
  • Vials
    • Glass vials
    • Plastic vials
  • Cartridges
  • Other consumables 
• Instruments
  • Type
    • Integrated systems
    • Standalone systems
  • Operation
    • Automated machines
    • Semi-automated and manual machines

Market, By Application

• Parenteral drug delivery
• Biologics manufacturing
• Personalized medicines
• Other applications

Market, By End Use

• Pharmaceutical and biopharmaceutical companies
• Contract manufacturing organizations
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE